Compare VABK & ADAG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | VABK | ADAG |
|---|---|---|
| Founded | 1998 | 2011 |
| Country | United States | China |
| Employees | N/A | N/A |
| Industry | Major Banks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 235.8M | 260.3M |
| IPO Year | 2013 | 2020 |
| Metric | VABK | ADAG |
|---|---|---|
| Price | $45.50 | $3.59 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 4 |
| Target Price | N/A | ★ $8.25 |
| AVG Volume (30 Days) | 7.2K | ★ 353.4K |
| Earning Date | 04-23-2026 | 04-01-2026 |
| Dividend Yield | ★ 3.39% | N/A |
| EPS Growth | ★ 12.70 | N/A |
| EPS | ★ 0.97 | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $47.23 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $36.60 | $1.44 |
| 52 Week High | $48.58 | $4.85 |
| Indicator | VABK | ADAG |
|---|---|---|
| Relative Strength Index (RSI) | 69.87 | 42.97 |
| Support Level | $38.18 | $3.21 |
| Resistance Level | $48.18 | $4.09 |
| Average True Range (ATR) | 1.05 | 0.43 |
| MACD | 0.21 | -0.08 |
| Stochastic Oscillator | 100.00 | 3.79 |
Virginia National Bankshares Corp is a bank holding company engaged in commercial and retail banking. The bank offers a range of banking and related financial services, including checking accounts, negotiable order of withdrawal accounts, money market deposit accounts, certificates of deposit, individual retirement accounts, and other depository services. Its segments include the Bank, VNB Trust and Estate Services, and Masonry Capital. The Bank's commercial banking activities involve making loans, taking deposits, and offering related services to individuals, businesses, and charitable organizations.
Adagene Inc is a platform-driven, clinical-stage biotechnology company focused on the discovery and development of novel antibody-based cancer immunotherapies. The Company leverages computational biology to design and develop novel antibodies. Powered by its Dynamic Precision Library (DPL) platform, which fuels its NEObody, SAFEbody, and POWERbody technologies, it is developing a pipeline of immunotherapies. Its candidate, ADG126 (muzastotug), an anti-CTLA-4 SAFEbody, is in phase 1b/2 and phase 2 clinical development for metastatic microsatellite-stable colorectal cancer. Its clinical-stage products include ADG126 and ADG116, investigational fully human anti-CTLA-4 mAbs generated through SAFEbody and NEObody technologies.